HRP20141023T1 - Novi postupak sinteze ivabradina i njegovih adicijskih soli sa farmaceutski prihvatljivom kiselinom - Google Patents
Novi postupak sinteze ivabradina i njegovih adicijskih soli sa farmaceutski prihvatljivom kiselinom Download PDFInfo
- Publication number
- HRP20141023T1 HRP20141023T1 HRP20141023AT HRP20141023T HRP20141023T1 HR P20141023 T1 HRP20141023 T1 HR P20141023T1 HR P20141023A T HRP20141023A T HR P20141023AT HR P20141023 T HRP20141023 T HR P20141023T HR P20141023 T1 HRP20141023 T1 HR P20141023T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- optionally substituted
- heteroaromatic
- aromatic
- image
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 14
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title claims 2
- 229960003825 ivabradine Drugs 0.000 title claims 2
- 239000002253 acid Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 14
- 230000015572 biosynthetic process Effects 0.000 claims 11
- 238000003786 synthesis reaction Methods 0.000 claims 11
- 239000003054 catalyst Substances 0.000 claims 10
- 238000006268 reductive amination reaction Methods 0.000 claims 8
- 125000001931 aliphatic group Chemical group 0.000 claims 7
- 229910052742 iron Inorganic materials 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000001033 ether group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- -1 or • -NH group Chemical group 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical compound OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 claims 2
- JHYNEQNPKGIOQF-UHFFFAOYSA-N 3,4-dihydro-2h-phosphole Chemical compound C1CC=PC1 JHYNEQNPKGIOQF-UHFFFAOYSA-N 0.000 claims 1
- ADLVDYMTBOSDFE-UHFFFAOYSA-N 5-chloro-6-nitroisoindole-1,3-dione Chemical group C1=C(Cl)C([N+](=O)[O-])=CC2=C1C(=O)NC2=O ADLVDYMTBOSDFE-UHFFFAOYSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 150000004982 aromatic amines Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002527 isonitriles Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- GWLJTAJEHRYMCA-UHFFFAOYSA-N phospholane Chemical compound C1CCPC1 GWLJTAJEHRYMCA-UHFFFAOYSA-N 0.000 claims 1
- 150000008300 phosphoramidites Chemical class 0.000 claims 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 125000005555 sulfoximide group Chemical group 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2282—Unsaturated compounds used as ligands
- B01J31/2295—Cyclic compounds, e.g. cyclopentadienyls
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Catalysts (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Postupak za sintezu ivabradina formule (I):
[image]
naznačen time, da je spoj formule (V):
[image]
podvrgnut reakciji redukcijske aminacije sa aminom formule (VI):
[image]
u prisutnosti katalizatora na bazi željeza formule (VII):
[image]
pri čemu R1, R2, R3 i R4 neovisno predstavljaju:
• atom vodika, ili
• skupinu - SiR5R6R7, pri čemu R5, R6 i R7 neovisno predstavljaju po izboru supstituiranu, ravnu ili razgrananu (C1-C6)alkilnu skupinu ili po izboru supstituiranu aromatičnu ili heteroaromatičnu skupinu, ili
• po izboru supstituiranu aromatičnu ili heteroaromatičnu skupinu, ili
• po izboru supstituiranu, ravnu ili razgrananu (C1-C6) alkilnu skupinu, ili
• skupinu koja privlači elektrone, ili
• amino skupinu koja je alifatska, aromatska, heteroaromatska ili nosi skupinu koja privlači elektrone ili
• alifatsku, aromatsku ili heteroaromatsku eter skupinu,
ili parovi R1 i R2, ili R2 i R3, ili R3 i R4 tvore, zajedno s atomom ugljika koji ih nosi, 3- do 7-eročlani karbocikl ili heterocikl,
X predstavlja:
• atom kisika, ili
• -NH skupinu, ili atom dušika koji je supstituiran s alifatskom, aromatskom, heteroaromatskom ili skupinom koja privlači elektrone ili
• -PH skupinu, ili fosforni atom koji je supstituiran s jednom ili više alifatskih, aromatskih ili skupina koje privlače elektrone, ili
• atom sumpora,
L1, L2 i L3 neovisno predstavljaju karbonil, nitril, izonitril, heteroaromat, fosfin, fosfit, fosfonit, fosforamidit, fosfonit, fosfolan, fosfolen, alifatski amin, aromatski amin, heteroaromatski amin, skupinu koja privlači elektrone i nosi amin, alifatski eter, aromatski eter, heteroaromatski eter, sulfon, sulfoksid ili sulfoksimin skupinu ili N-heterocikličnu karbensku skupinu koja ima jednu od sljedeće dvije formule:
[image]
pri čemu Y i Z neovisno predstavljaju atom sumpora ili atom kisika ili skupinu NR8 i R8 predstavlja po izboru supstituiranu alkil skupinu ili po izboru supstituiranu aromatsku ili heteroaromatsku skupinu,
K predstavlja atom ugljika ili atom dušika,
R9 i R10 neovisno predstavljaju atom vodika, po izboru supstituiranu alkilnu skupinu, po izboru supstituiranu aromatičnu ili heteroaromatičnu skupinu, atom halogena, alifatsku, aromatsku ili heteroaromatsku etersku skupinu, alifatsku, aromatsku ili heteroaromatsku amino skupinu, ili par R9 i R10 tvori zajedno s atomima koji ih nose, 3- do 7-člani karbocikl ili heterocikl, ili
[image]
pri čemu R11 i R12 neovisno predstavljaju po izboru supstituiranu alkilnu skupinu ili po izboru supstituiranu aromatsku ili heteroaromatsku skupinu, a n je 1 ili 2, u prisutnosti ili bez trimetilamin N-oksida, pod tlakom dihidrogena od 1 do 20 bara, u organskom otapalu ili smjesi organskih otapala, pri temperaturi od 25 do 100°C.
2. Postupak sinteze u skladu s patentnim zahtjevom 1, naznačen time, da katalizator na bazi željeza ima sljedeću opću formulu:
[image]
pri čemu R2 i R3 svaki predstavlja atom vodika ili pak zajedno s atomom ugljika koji ih nosi, tvori 3 do 7-člani karbocikl ili heterocikl, a R1 i R4 neovisno predstavljaju:
• bilo skupinu -SiR5R6R7, pri čemu R5, R6 i R7 neovisno predstavljaju po izboru supstituiranu, ravnu ili razgrananu (C1-C6)alkil skupinu ili po izboru supstituiranu arilnu skupinu,
• ili po izboru supstituiranu aromatsku ili heteroaromatsku skupinu,
• ili po izboru supstituiranu, ravnu ili razgrananu (C1-C6)alkil skupinu.
3. Postupak sinteze u skladu s patentnim zahtjevom 2, naznačen time, da je katalizator na bazi željeza odabran između:
[image]
4. Postupak sinteze u skladu s patentnim zahtjevom 1, naznačen time, da katalizator na bazi željeza ima sljedeću opću formulu:
[image]
pri čemu R2 i R3 predstavljaju atom vodika ili pak zajedno s atomom ugljika koji ih nosi, tvore 3 do 7-člani karbocikl ili heterocikl, a R1 i R4 neovisno predstavljaju:
• bilo skupinu -SiR5R6R7, pri čemu R5, R6 i R7 neovisno predstavljaju po izboru supstituiranu, ravnu ili razgrananu (C1-C6)alkilnu skupinu ili po izboru supstituiranu aromatsku ili heteroaromatsku skupinu,
• ili po izboru supstituiranu aromatsku ili heteroaromatsku skupinu,
• ili po izboru supstituiranu, ravnu ili razgrananu (C1-C6)alkil skupinu.
5. Postupak sinteze u skladu s patentnim zahtjevom 4, naznačen time, da je katalizator na bazi željeza je odabran između:
[image]
6. Postupak prema zahtjevu 1, naznačen time, da katalizator na bazi željeza ima sljedeću formulu:
[image]
7. Postupak prema zahtjevu 1, naznačen time, da katalizator na bazi željeza ima sljedeću formulu:
[image]
8. Postupak sinteze u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time, da je količina katalizatora korištenog u reakciji redukcijske aminacije od 1 mol% do 10 mol% u odnosu na aldehid.
9. Postupak sinteze u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da je količina N-oksida korištenog u reakciji redukcijske aminacije od 0 do 3 ekvivalenta u odnosu na katalizator.
10. Postupak sinteze u skladu s patentnim zahtjevom 9, naznačen time, da je količina trimetilamin N-oksida koji se koristi u reakciji redukcijske aminacije od 0,5 do 1,5 ekvivalenata u odnosu na katalizator.
11. Postupak sinteze u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time, da je tlak dihidrogena u reakciji redukcijske aminacije od 1 do 10 bara.
12. Postupak sinteze u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time, da je otapalo u reakciji redukcijske aminacije alkohol.
13. Postupak sinteze u skladu s patentnim zahtjevom 12, naznačen time, da je otapalo u reakciji redukcijske aminacije etanol.
14. Postupak sinteze u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time, da je temperatura reakcije redukcijske aminacije od 50 do 100°C.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1103933A FR2984319B1 (fr) | 2011-12-20 | 2011-12-20 | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20141023T1 true HRP20141023T1 (hr) | 2014-12-05 |
Family
ID=47115640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20141023AT HRP20141023T1 (hr) | 2011-12-20 | 2014-10-23 | Novi postupak sinteze ivabradina i njegovih adicijskih soli sa farmaceutski prihvatljivom kiselinom |
Country Status (35)
Country | Link |
---|---|
US (1) | US8513410B2 (hr) |
EP (1) | EP2607353B1 (hr) |
JP (1) | JP5670406B2 (hr) |
KR (1) | KR101470879B1 (hr) |
CN (1) | CN103172566B (hr) |
AR (1) | AR088678A1 (hr) |
AU (1) | AU2012244188B2 (hr) |
BR (1) | BR102012028614A2 (hr) |
CA (1) | CA2795741C (hr) |
CL (1) | CL2012003136A1 (hr) |
CY (1) | CY1115682T1 (hr) |
DK (1) | DK2607353T3 (hr) |
EA (1) | EA026510B1 (hr) |
ES (1) | ES2525032T3 (hr) |
FR (1) | FR2984319B1 (hr) |
GE (1) | GEP20156350B (hr) |
HK (1) | HK1186733A1 (hr) |
HR (1) | HRP20141023T1 (hr) |
JO (1) | JO3031B1 (hr) |
MA (1) | MA34276B1 (hr) |
MD (1) | MD4336C1 (hr) |
MX (1) | MX2012012938A (hr) |
MY (1) | MY170662A (hr) |
PE (1) | PE20131097A1 (hr) |
PL (1) | PL2607353T3 (hr) |
PT (1) | PT2607353E (hr) |
RS (1) | RS53541B1 (hr) |
SA (1) | SA112330994B1 (hr) |
SG (1) | SG191471A1 (hr) |
SI (1) | SI2607353T1 (hr) |
TW (1) | TWI440627B (hr) |
UA (1) | UA111329C2 (hr) |
UY (1) | UY34423A (hr) |
WO (1) | WO2013093220A1 (hr) |
ZA (1) | ZA201208160B (hr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2988720B1 (fr) * | 2012-03-27 | 2014-03-14 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
CN105669554A (zh) * | 2016-02-22 | 2016-06-15 | 徐建立 | 一种盐酸伊伐布雷定杂质及其制备方法和应用 |
FR3071833B1 (fr) * | 2017-09-29 | 2020-01-03 | Universite Paris-Sud | Nouveau procede de synthese d'amines tertiaires dissymetriques |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
US6225487B1 (en) * | 1998-04-17 | 2001-05-01 | Symyx Technologies, Inc. | Ancillary ligands and metal complexes, catalysts and compositions using same and methods of testing |
US6521793B1 (en) * | 1998-10-08 | 2003-02-18 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
EP1595888A1 (en) * | 2004-05-11 | 2005-11-16 | Degussa AG | Cycloolefin phosphine ligands and their use in catalysis |
ES2381771T3 (es) * | 2006-11-30 | 2012-05-31 | Cadila Healthcare Limited | Procedimiento para la preparación de hidrocloruro de ivabradina |
US7857994B2 (en) | 2007-05-30 | 2010-12-28 | GE Lighting Solutions, LLC | Green emitting phosphors and blends thereof |
RU2473544C2 (ru) * | 2007-05-30 | 2013-01-27 | Инд-Свифт Лабораториз Лимитед | Способ получения ивабрадина гидрохлорида и его полиморфных модификаций |
FR2920773B1 (fr) * | 2007-09-11 | 2009-10-23 | Servier Lab | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2933975B1 (fr) * | 2008-07-17 | 2011-02-18 | Servier Lab | Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
FR2935381B1 (fr) * | 2008-08-29 | 2010-12-17 | Servier Lab | Nouveau procede de resolution des enantiomerees du (3,4-dimethoxy-bicyclo°4.2.0!octa-1,3,5-trien-7-yl)nitrile et application a la synthese de l'ivabradine |
FR2940287B1 (fr) * | 2008-12-24 | 2010-12-24 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
FR2941695B1 (fr) * | 2009-02-04 | 2011-02-18 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
-
2011
- 2011-12-20 FR FR1103933A patent/FR2984319B1/fr not_active Expired - Fee Related
-
2012
- 2012-10-23 JO JOP/2012/0320A patent/JO3031B1/ar active
- 2012-10-23 SG SG2012078705A patent/SG191471A1/en unknown
- 2012-10-24 AU AU2012244188A patent/AU2012244188B2/en not_active Ceased
- 2012-10-24 CA CA2795741A patent/CA2795741C/fr not_active Expired - Fee Related
- 2012-10-25 PE PE2012002077A patent/PE20131097A1/es active IP Right Grant
- 2012-10-30 ZA ZA2012/08160A patent/ZA201208160B/en unknown
- 2012-10-30 UY UY0001034423A patent/UY34423A/es not_active Application Discontinuation
- 2012-10-30 MY MYPI2012700844A patent/MY170662A/en unknown
- 2012-10-31 MD MDA20120094A patent/MD4336C1/ro not_active IP Right Cessation
- 2012-11-06 TW TW101141192A patent/TWI440627B/zh not_active IP Right Cessation
- 2012-11-07 MA MA35353A patent/MA34276B1/fr unknown
- 2012-11-07 AR ARP120104179A patent/AR088678A1/es unknown
- 2012-11-07 MX MX2012012938A patent/MX2012012938A/es active IP Right Grant
- 2012-11-08 UA UAA201212746A patent/UA111329C2/uk unknown
- 2012-11-08 BR BR102012028614-9A patent/BR102012028614A2/pt not_active IP Right Cessation
- 2012-11-08 KR KR1020120126314A patent/KR101470879B1/ko active IP Right Grant
- 2012-11-08 CN CN201210443036.8A patent/CN103172566B/zh not_active Expired - Fee Related
- 2012-11-08 GE GEAP201212889A patent/GEP20156350B/en unknown
- 2012-11-08 CL CL2012003136A patent/CL2012003136A1/es unknown
- 2012-11-09 PL PL12191902T patent/PL2607353T3/pl unknown
- 2012-11-09 RS RSP20140509 patent/RS53541B1/en unknown
- 2012-11-09 WO PCT/FR2012/000451 patent/WO2013093220A1/fr active Application Filing
- 2012-11-09 SI SI201230089T patent/SI2607353T1/sl unknown
- 2012-11-09 DK DK12191902.1T patent/DK2607353T3/en active
- 2012-11-09 PT PT121919021T patent/PT2607353E/pt unknown
- 2012-11-09 EA EA201201385A patent/EA026510B1/ru not_active IP Right Cessation
- 2012-11-09 EP EP12191902.1A patent/EP2607353B1/fr active Active
- 2012-11-09 ES ES12191902.1T patent/ES2525032T3/es active Active
- 2012-11-09 JP JP2012247143A patent/JP5670406B2/ja active Active
- 2012-11-09 US US13/673,145 patent/US8513410B2/en not_active Expired - Fee Related
- 2012-11-10 SA SA112330994A patent/SA112330994B1/ar unknown
-
2013
- 2013-12-23 HK HK13114205.7A patent/HK1186733A1/zh not_active IP Right Cessation
-
2014
- 2014-10-14 CY CY20141100832T patent/CY1115682T1/el unknown
- 2014-10-23 HR HRP20141023AT patent/HRP20141023T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME01098B (me) | VIŠESTRUKO SUPSTITUISANI DERIVATI 2-ARIL-6-FENILIMIDAZO [1,2- α] PIRIDINA, I NJIHOVO DOBIJANJE I TERAPEUTSKA PRIMENA | |
HRP20141023T1 (hr) | Novi postupak sinteze ivabradina i njegovih adicijskih soli sa farmaceutski prihvatljivom kiselinom | |
AR049401A1 (es) | Aza-biciclononanos | |
AR048008A1 (es) | Procesos para la preparacion de inhibidores de caspasa derivados de los mismos | |
ES2242621T3 (es) | Proceso para la produccion de aminas por aminacion reductora de compuestos de carbonico catalizada homogeneamente. | |
MA32247B1 (fr) | Derives de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines polysubstitues, leur préparation et leur application en thérapeutique | |
RS51133B (sr) | Novi triciklični derivati, postupak za njihovu proizvodnju i farmaceutske smeše koje ih sadrže | |
MY157073A (en) | Conversion method | |
BR112014016322B1 (pt) | Processo para a preparação de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina | |
UY31093A1 (es) | Compuestos de ariloazol-2-il cianoetilamino, método para prepararlos y método para utilizarlos | |
WO2013042973A3 (ko) | I-선 포토레지스트 조성물 및 이를 이용한 미세패턴 형성 방법 | |
Bhutani et al. | Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs | |
Naeimi et al. | Thioether-based copper (I) Schiff base complex as a catalyst for a direct and asymmetric A3-coupling reaction | |
RS53169B (en) | PIRAZOLE COMPOUNDS, THE PROCESS FOR THEIR PRODUCTION AND THE HERBICIDES CONTAINING THEM | |
Matveeva et al. | Efficient synthesis of racemic β-aminophosphonates via aza-Michael reaction in water | |
CU24030B1 (es) | Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen | |
HRP20170416T1 (hr) | Sintetski postupci i postupci pročišćavanja spojeva fosfaplatine i njihova uporaba | |
WO2007119001A3 (fr) | Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique | |
Milen et al. | T3P®‐Mediated One‐Pot Synthesis of Bis (α‐aminophosphonates) | |
SI2681192T1 (en) | Synthesis of the 2-carboxamide cycloamino derivatives derivatives | |
TW200606588A (en) | Resist composition and process for forming resist pattern | |
MX2010013938A (es) | Derivados triciclicos sustituidos contra las enfermedades neurodegenerativas. | |
AR078135A1 (es) | Un proceso para la preparacion de derivados de cianoalquilpropionato. | |
RU2018125748A (ru) | Пролекарство на основе уридинфосфорамида, способ его получения и его применения в медицине | |
Khan et al. | Asymmetric synthesis of α-aminophosphonate esters by the addition of dialkyl phosphites to tert-butanesulfinyl imines |